Single nucleotide polymorphisms

Multiple sclerosis (MS) is a prevalent demyelinating disease that primarily affects young adults. Within the realm of MS patients, the extent of disease severity and progression differs greatly across individuals. Studies conducted on post-mortem tissue samples have characterized complex lesion types that diverge significantly on the composition of oligodendrocyte (OLG) lineage cells and their degrees of remyelination, both across different individuals and within each MS patient1. To date, the intrinsic genetic factors that potentially impact OLG-mediated de- and re-myelination in MS lesions,

Alzheimer’s disease (AD) is the most common and progressive type of brain disorder that affects parts of the brain responsible for memory, speaking, thinking, and many other important functions. Apart from its common risk factors such as aging, environment, and lifestyle elements, the risk of developing AD largely depends on gene variants, which present a promising opportunity for identifying novel diagnostic and therapeutic biomarkers. Early studies have revealed numerous SNPs simultaneously associated with AD and other diseases such as Parkinson’s disease, stroke, multiple sclerosis, and mor